Daratumumab (anti-CD38) induces loss of CD38 on red blood cells
- 1 June 2017
- journal article
- Published by American Society of Hematology in Blood
- Vol. 129 (22), 3033-3037
- https://doi.org/10.1182/blood-2016-11-749432
Abstract
No abstract availableThis publication has 23 references indexed in Scilit:
- Pathobiology of Transfusion ReactionsAnnual review of pathology, 2015
- Antigen Modulation Confers Protection to Red Blood Cells from Antibody through Fcγ Receptor LigationThe Journal of Immunology, 2013
- A novel role for C3 in antibody-induced red blood cell clearance and antigen modulationBlood, 2013
- Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological TumorsThe Journal of Immunology, 2011
- Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumabHaematologica, 2010
- Antigen Loss From Antibody-Coated Red Blood CellsTransfusion Medicine Reviews, 2009
- Nonhemolytic antigen loss from red blood cells requires cooperative binding of multiple antibodies recognizing different epitopesBlood, 2007
- Nonhemolytic antibody-induced loss of erythrocyte surface antigenBlood, 2005
- CD38/CD31, a Receptor/Ligand System Ruling Adhesion and Signaling in Human LeukocytesPublished by S. Karger AG ,2000
- Transient Production of Anti‐LW by LW‐positive PeopleTransfusion, 1971